{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,11,15]],"date-time":"2023-11-15T12:44:50Z","timestamp":1700052290230},"reference-count":35,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2007,10,29]],"date-time":"2007-10-29T00:00:00Z","timestamp":1193616000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Hematological Oncology"],"published-print":{"date-parts":[[2008,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Essential thrombocythaemia (ET) is an acquired myeloproliferative disorder. The phenotypic and biological heterogeneity of ET can make management of individual cases problematic, especially in the era of changing ideas on the molecular pathogenesis of this disease process. This case discussion will explore the evidence base and rationale that guides treatment of a 46\u2010year\u2010old individual with ET presenting with an ischaemic episode. Copyright \u00a9 2007 John Wiley &amp; Sons, Ltd.<\/jats:p>","DOI":"10.1002\/hon.835","type":"journal-article","created":{"date-parts":[[2007,10,29]],"date-time":"2007-10-29T11:14:01Z","timestamp":1193656441000},"page":"3-7","source":"Crossref","is-referenced-by-count":2,"title":["How would I manage a case of essential thrombocythaemia presenting with an ischaemic toe"],"prefix":"10.1002","volume":"26","author":[{"given":"DP","family":"McLornan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"MF","family":"McMullin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2007,10,29]]},"reference":[{"issue":"1","key":"e_1_2_1_2_2","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1055\/s-0038-1657600","article-title":"Therapeutic dilemmas: balancing the risks of bleeding, thrombosis, and leukemic transformation in myeloproliferative disorders (MPD)","volume":"78","author":"Murphy S","year":"1997","journal-title":"Thromb Haemost"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-04-083501"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature03546"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2005.03.023"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)71142-9"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa051113"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)67785-9"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.10634"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2005.05764.x"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-09-046342"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.22663"},{"issue":"3","key":"e_1_2_1_13_2","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1182\/blood-2006-12-064287","article-title":"Clinical profile of homozygous JAK2V617F mutation in patients with polycythemia vera or essential thrombocythemia","volume":"110","author":"Vannucchi AM","year":"2007","journal-title":"Blood"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1097\/00001721-200401000-00004"},{"key":"e_1_2_1_15_2","first-page":"111a","article-title":"V Leidin mutations,prothrombin and methylene\u2010tetrahydrofolate reductase are not risk factors for thromboembolic disease in essential thrombocythemia","volume":"94","author":"Dicato M","year":"1999","journal-title":"Blood"},{"key":"e_1_2_1_16_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.10153"},{"key":"e_1_2_1_17_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa043800"},{"key":"e_1_2_1_18_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1990.8.3.556"},{"key":"e_1_2_1_19_2","doi-asserted-by":"publisher","DOI":"10.1053\/sonc.2002.33756"},{"key":"e_1_2_1_20_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2401270"},{"key":"e_1_2_1_21_2","doi-asserted-by":"publisher","DOI":"10.4065\/81.2.159"},{"key":"e_1_2_1_22_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-2007-996119"},{"issue":"1","key":"e_1_2_1_23_2","first-page":"348a","article-title":"Epidemiological, diagnostic, therapeutic and prognostic aspects of essential thrombocythemia in a retrospective study of the GIMMC group in two thousand patients [abstract]","volume":"90","author":"Gugliotta L","year":"1997","journal-title":"Blood"},{"key":"e_1_2_1_24_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2002.03688.x"},{"key":"e_1_2_1_25_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404693"},{"key":"e_1_2_1_26_2","doi-asserted-by":"publisher","DOI":"10.1007\/s002770050555"},{"key":"e_1_2_1_27_2","doi-asserted-by":"publisher","DOI":"10.4065\/76.1.22"},{"key":"e_1_2_1_28_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V91.2.616"},{"key":"e_1_2_1_29_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa035572"},{"key":"e_1_2_1_30_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.10427"},{"key":"e_1_2_1_31_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2000.02188.x"},{"key":"e_1_2_1_32_2","doi-asserted-by":"publisher","DOI":"10.1177\/107602969900500210"},{"key":"e_1_2_1_33_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1997.d01-2127.x"},{"issue":"6","key":"e_1_2_1_34_2","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1182\/blood.V96.6.2093","article-title":"Interferon\u2010alpha directly represses megakaryopoiesis by inhibiting thrombopoietin\u2010induced signaling through induction of SOCS\u20101","volume":"96","author":"Wang Q","year":"2000","journal-title":"Blood"},{"issue":"2","key":"e_1_2_1_35_2","first-page":"215","article-title":"Practice guidelines for the therapy of essential thrombocythemia. A statement from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation","volume":"89","author":"Barbui T","year":"2004","journal-title":"Haematologica"},{"key":"e_1_2_1_36_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1997.3083125.x"}],"container-title":["Hematological Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhon.835","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hon.835","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,15]],"date-time":"2023-11-15T12:15:25Z","timestamp":1700050525000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/hon.835"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,10,29]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2008,1]]}},"alternative-id":["10.1002\/hon.835"],"URL":"https:\/\/doi.org\/10.1002\/hon.835","archive":["Portico"],"relation":{},"ISSN":["0278-0232","1099-1069"],"issn-type":[{"value":"0278-0232","type":"print"},{"value":"1099-1069","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,10,29]]}}}